Biologics Market Size, Share, Growth and Forecast, 2025-2035

Antibodies in cancer and immunology anchor biologic demand

The global biologics market was valued at USD 406.09 billion in 2025 and is projected to increase from USD 432.12 billion in 2026 to USD 755.83 billion by 2035, registering a CAGR of 6.41% during 2026–2035. Demand rests on monoclonal antibodies for cancer and immune diseases, vaccines, blood products and a growing set of cell and gene therapies for rare conditions. North America held the largest regional share, 48.0% in 2025, because the United States pays the highest prices for new antibodies and adopts specialty medicines first. Asia Pacific is the fastest-growing region at 7.73% a year, as China, Japan and South Korea expand domestic manufacturing and insurance coverage. The regulatory picture changed in October 2025, when U.S. regulators proposed dropping most comparative efficacy studies for biosimilars. As a result, competition for older antibodies should intensify while originators move value toward new mechanisms.

Which protein, cell and gene medicines does this analysis cover?

The analysis counts biologic medicines made in living systems, including monoclonal antibodies, fusion proteins, vaccines, blood products, bispecific antibodies and cell and gene therapies, valued at manufacturer selling prices. Hospitals and infusion centers buy most of these products through formularies and group contracts, while specialty and retail pharmacies dispense self-injected pens and syringes. Biosimilars are counted inside the relevant product groups, because they compete directly with the reference brands.

Synthetic small-molecule medicines, diagnostic reagents and research-use proteins sit outside the scope of this analysis. The value chain runs from cell line development and contract manufacturers through originator and biosimilar brands to wholesalers, specialty pharmacies, hospitals and payers that set reimbursement terms.

Monoclonal antibodies lead while bispecifics gain fastest

Why do monoclonal antibodies hold the largest product share?

Based on product, the market is categorized into monoclonal antibodies, fusion proteins, gene and cell therapy, vaccines, blood products, bispecific antibodies and others. Monoclonal Antibodies led with a 55.0% share of 2025 value, because they treat cancer, psoriasis, asthma, arthritis and many other chronic conditions. Bispecific Antibodies grow fastest at 15.13% a year, since T-cell engagers are winning approvals in lung cancer and blood cancers. Vaccines and blood products grow more slowly as mature, tender-driven categories.

Which therapy areas account for the most spending?

Based on indication, the market is categorized into oncology, autoimmune and inflammatory, infectious diseases, metabolic and endocrine, rare and genetic disorders and other applications. Oncology led with a 36.0% share of 2025 value, because checkpoint inhibitors and targeted antibodies are used across many tumor types, and about 1 in 5 people develop cancer in their lifetime. Rare & Genetic Disorders grow fastest at 7.38% a year, as gene therapies and antibodies for hemophilia and rare neuromuscular diseases reach patients. Infectious disease spending grows more slowly after the pandemic peak.

Will injected medicines keep dominating the route mix?

Based on route of administration, the market is categorized into oral and parenteral administration. Parenteral Administration led with a 95.0% share of 2025 value, because large proteins are broken down in the gut and must be injected or infused. Oral products grow fastest at 7.31% a year from a small base of oral vaccines and enzyme therapies. Within injectables, subcutaneous versions of infused antibodies are gaining ground in clinics and homes.

Where do hospitals and patients obtain these medicines?

Based on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies and online pharmacies. Hospital Pharmacies led with a 58.0% share of 2025 value, because infused cancer antibodies, cell therapies and blood products are given in hospitals. Online Pharmacies grow fastest at 7.78% a year, as specialty pharmacies ship self-injected immunology pens directly to homes. Retail pharmacies keep a steady share through vaccines and self-injected products.

Cancer burden and immune disease care lift demand

How does the rising cancer burden lift antibody demand?

Cancer is the largest source of biologic spending, because antibodies now feature in first-line care for many tumors. The World Health Organization reported in February 2024 that there were an estimated 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, and 53.5 million people were alive within five years of a diagnosis. The agency also projected 35 million new cases in 2050, a 77% increase from 2022. As a result, demand for checkpoint inhibitors, antibody combinations and newer cancer medicines rises through 2035.

Why are immune diseases widening the treatment pool?

Immune and inflammatory diseases form a large and expanding treatment pool, because new antibodies reach conditions that once had no targeted option. In September 2024, Sanofi announced that Dupixent was approved in the U.S. as the first biologic medicine for patients with chronic obstructive pulmonary disease and an eosinophilic phenotype. This approval opened a large respiratory population to antibody therapy. In turn, each new indication extends the use of established antibodies, which raises patient numbers without new manufacturing platforms.

Download Free Sample

How are rare disease approvals adding high-value patients?

Rare and genetic disorders add a small number of patients with very high value per treatment, because few alternatives exist. In October 2024, U.S. regulators approved Pfizer's Hympavzi (marstacimab), a once-weekly antibody for hemophilia A or B without inhibitors. In April 2025, Johnson & Johnson won U.S. approval for Imaavy (nipocalimab) for generalized myasthenia gravis. These approvals show how antibodies and gene therapies are moving into conditions where patients have long relied on older treatments.

Why does easier biosimilar development raise volumes?

Biosimilars raise treated volumes, because lower prices let payers extend antibody therapy to more patients. In October 2025, the U.S. Food and Drug Administration proposed that most biosimilars no longer need comparative efficacy studies, which it said cost about USD 24 million on average and take one to three years. This change shortens development timelines and lowers entry costs for biosimilar makers. As a result, volumes should grow faster than prices for antibodies that lose exclusivity through the early 2030s.

Subcutaneous dosing and T-cell engagers reshape therapy

Is subcutaneous dosing shifting care out of infusion chairs?

Subcutaneous dosing is the clearest shift in biologic administration, because it reduces chair time in crowded infusion centers. In September 2025, Merck announced that the U.S. Food and Drug Administration had approved Keytruda Qlex for subcutaneous use across 38 solid tumor indications, with an injection that can take as little as 1 minute. This shift lets clinics treat more patients per day and gives originators a new formulation as patents on intravenous versions approach expiry. In turn, subcutaneous versions are spreading across oncology and immunology portfolios.

Are T-cell engagers emerging in solid tumors?

T-cell engagers are emerging as a new standard in hard-to-treat cancers, because they redirect the immune system to tumor cells. In May 2024, Amgen announced U.S. approval of Imdelltra (tarlatamab) as the first T-cell engager for extensive-stage small cell lung cancer. Amgen noted that more than 2.4 million people are diagnosed with lung cancer worldwide each year, which defines a large target population. This rise of engineered formats is why bispecific antibodies grow faster than any other product group in this analysis.

Download Free Sample

Where can biosimilar makers capture growth?

Biosimilar makers have a clear opening as major antibodies lose exclusivity in the United States, Europe and Japan through the early 2030s. Lower development costs under the proposed U.S. guidance make it practical to target smaller brands that were previously uneconomic. This opportunity is largest in immunology and oncology, where several high-value antibodies face competition before 2035. In turn, payers can redirect savings toward newer and costlier therapies such as engagers and cell therapies.

Can cell and gene therapies open a premium rare disease niche?

Cell and gene therapies offer an opening for companies that can deliver one-time or long-lasting treatment for severe conditions. These therapies command the highest prices per patient in medicine, and specialized treatment centers in North America and Europe are expanding capacity. However, uptake depends on outcomes-based payment models that spread costs over several years. If payers adopt such models widely, this segment can grow much faster than the overall market through 2035.

Biosimilar entry and payer pressure restrain prices

How does biosimilar entry erode originator prices?

Biosimilar entry erodes prices for established antibodies, because payers switch patients to cheaper versions once competition arrives. In Europe, tenders often move most volume to biosimilars within a few years of entry, and the United States is following the same pattern in immunology. Monoclonal antibodies, which held 55.0% of 2025 value, face the greatest exposure to this switching. This pressure means rising patient numbers do not translate into proportional value growth. As a result, originators defend franchises with new formulations, combination regimens and next-generation antibodies.

Why does payer pressure limit launch prices?

Payer pressure limits launch prices, because biologics account for a large share of drug budgets in most high-income countries. Health technology assessment bodies in Europe and price negotiation rules in the United States both target the highest-spending products. This scrutiny lengthens the time from approval to full reimbursement for new antibodies and cell therapies. In turn, companies must show clear gains in survival or quality of life to secure premium pricing.

Does manufacturing complexity constrain supply?

Manufacturing complexity constrains supply, because biologics depend on living cells, sterile processing and long quality release times. Building a new large-scale bioreactor plant takes several years and a heavy capital commitment, so capacity cannot respond quickly to new approvals. Cell and gene therapies face even tighter limits, since many products are made for each patient individually. However, contract manufacturers and new regional plants are gradually easing these bottlenecks.

Why does cold chain logistics raise costs?

Cold chain logistics raise distribution costs, because most biologics must stay refrigerated or frozen from the plant to the patient. This requirement is hardest to meet in rural areas of Latin America, Africa and South Asia, where reliable refrigeration is not always available. Temperature excursions can destroy entire shipments, which adds insurance, monitoring and packaging costs for suppliers. As a result, access in lower-income regions lags behind approvals in North America and Europe.

North America leads as Asia Pacific builds capacity

Why does North America hold the largest regional share?

North America held a 48.0% share of 2025 value and grows at 6.03% a year through 2035. The United States drives this position, because new antibodies, engagers and cell therapies launch there first and sell at the highest net prices in the world. Specialty pharmacy networks and infusion centers support fast uptake of new products. However, Medicare price negotiation and faster biosimilar switching hold regional growth under the worldwide pace.

How fast is Asia Pacific catching up?

Asia Pacific held a 19.0% share of 2025 value and is the fastest-growing region at 7.73% a year from 2026 to 2035, ahead of 7.13% in the Middle East and Africa. China and South Korea are building large domestic biologic manufacturing bases, and Chinese developers increasingly license antibodies and engagers to global companies. Japan adds a high-value market with rapid uptake of cancer and immunology antibodies. In turn, wider insurance coverage in China and India lifts the number of patients receiving antibody therapy.

Download Free Sample

What shapes demand across Europe?

Europe held a 26.0% share of 2025 value and grows at 5.93% a year, the slowest of the five regions and below the 6.03% rate in North America. Health technology assessment and tenders hold down prices across Germany, France, Italy, Spain and the United Kingdom, and biosimilar uptake is the highest in the world. However, the region remains a major production hub for antibodies, vaccines and blood products, which supports exports and local supply. New cell and gene therapies add value in specialized centers.

Where is Latin America adding demand?

Latin America held a 4.0% share of 2025 value and grows at 6.93% a year through 2035, faster than both North America and Europe. Brazil and Mexico lead regional demand, supported by public programs that buy vaccines, insulin and biosimilar antibodies centrally.

What limits growth in the Middle East and Africa?

The Middle East and Africa held a 3.0% share of 2025 value and grows at 7.13% a year through 2035. Gulf states add high-value demand for cancer and immunology antibodies in modern tertiary hospitals. In much of Africa, vaccines and blood products dominate spending, while cold chain gaps limit access to newer therapies.

Download Free Sample

Approvals and rule changes redraw protein medicine supply

Engineered antibodies and cell therapies set the pipeline

• Bispecific T-cell engagers such as tarlatamab, first approved in 2024, bind a tumor target and an immune cell at the same time, which directs the patient's own T cells against the cancer.
• Subcutaneous co-formulations combine an antibody with an enzyme that eases absorption under the skin, which turns long infusions into short injections.
• Antibody-drug conjugates attach a potent drug to a targeting antibody, which delivers treatment to tumor cells while sparing more healthy tissue.
• FcRn blockers lower levels of harmful antibodies in autoimmune diseases, which has opened new treatment options for myasthenia gravis since 2025.

Large originators defend franchises against biosimilars

Competition is concentrated among large originators that hold leading antibody franchises in cancer, immunology and metabolic disease. Merck & Co., Bristol-Myers Squibb, AstraZeneca and Roche lead cancer antibodies, while AbbVie, Johnson & Johnson and Sanofi hold large immunology portfolios. Amgen competes in both areas and also develops biosimilars, and Pfizer spans vaccines, rare disease antibodies and oncology. Novo Nordisk and Eli Lilly lead protein and peptide medicines for diabetes and obesity, and both are expanding manufacturing capacity. Originators differentiate through label expansions, subcutaneous versions and engineered successors, while biosimilar makers win on cost and supply reliability. However, biosimilar entry and price negotiation rules push every originator to refresh its portfolio before key patents expire, which keeps licensing and acquisition activity high through 2035.

Companies profiled and their roles in this market

Value shifts toward engagers and convenient dosing

Credence Research's view is that value in biologics will concentrate in two places through 2035, engineered antibody formats and convenient dosing of established medicines. Bispecific engagers and antibody-drug conjugates command premium prices, because they work where earlier treatments fail. While the overall market grows at 6.41% a year, biosimilars will take a rising share of volume in immunology and oncology, and price erosion will slow value growth for older antibodies. The originators best placed for 2035 are those that move patients to subcutaneous or engineered successors before biosimilars arrive.

How Credence Research sized protein medicine spending

Biologic values in this edition use 2025 as the base year and 2026 to 2035 as the forecast window. Market values come from the Credence Research model, which adds up spending by product, indication, route of administration and distribution channel. Regional and segment splits are Credence Research estimates informed by regulator approvals and guidance, World Health Organization cancer statistics, and company press releases. No primary interviews or surveys were used in preparing this edition of the report.

Protein and cell medicine spending outlook to 2035

By 2035, the biologics market is projected to reach USD 755.83 billion, with growth tilted toward cancer antibodies, engineered formats and rare disease therapy, as the World Health Organization expects 35 million new cancer cases a year by 2050. Biosimilars are likely to widen access in immunology and oncology, although they will slow value growth for older brands. Asia Pacific should add the most new capacity and patients, while North America keeps the highest value per patient. As a result, the strongest positions will belong to companies that refresh antibody franchises before patents lapse and secure enough cell culture capacity.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.